Precipio, Inc. PRPO
We take great care to ensure that the data presented and summarized in this overview for Precipio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRPO
View allLatest Institutional Activity in PRPO
Top Purchases
Top Sells
About PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Insider Transactions at PRPO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Richard A Sandberg Director |
SELL
Open market or private sale
|
Direct |
2,000
-10.8%
|
$12,000
$6.28 P/Share
|
|
Oct 15
2024
|
David Seth Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,982
+4.0%
|
$11,892
$6.62 P/Share
|
|
Oct 15
2024
|
Jeffrey Cossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,586
+11.41%
|
$9,516
$6.62 P/Share
|
|
Oct 15
2024
|
Richard A Sandberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,492
+11.86%
|
$14,952
$6.62 P/Share
|
|
Oct 15
2024
|
Christina Rizopoulos Valauri Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,472
+22.67%
|
$8,832
$6.62 P/Share
|
|
Oct 15
2024
|
Ronald Asbury Andrews Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,510
+11.95%
|
$9,060
$6.62 P/Share
|
|
Jul 15
2024
|
Ronald Asbury Andrews Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,157
+18.32%
|
$8,628
$4.63 P/Share
|
|
Jul 15
2024
|
David Seth Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,832
+5.85%
|
$11,328
$4.63 P/Share
|
|
Jul 15
2024
|
Jeffrey Cossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,265
+99.56%
|
$9,060
$4.63 P/Share
|
|
Jul 15
2024
|
Christina Rizopoulos Valauri Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,103
+37.21%
|
$8,412
$4.63 P/Share
|
|
Apr 15
2024
|
Richard A Sandberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,913
+26.94%
|
$35,478
$6.66 P/Share
|
|
Apr 15
2024
|
Kathleen Laporte Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,693
+49.04%
|
$58,158
$6.7 P/Share
|
|
Apr 15
2024
|
Christina Rizopoulos Valauri Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,446
+50.0%
|
$8,676
$6.74 P/Share
|
|
Apr 15
2024
|
Ronald Asbury Andrews Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,153
+29.71%
|
$18,918
$6.66 P/Share
|
|
Apr 15
2024
|
David Seth Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,575
+7.72%
|
$21,450
$6.67 P/Share
|
|
Apr 15
2024
|
Jeffrey Cossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,143
+49.04%
|
$48,858
$6.7 P/Share
|
|
Oct 27
2023
|
Douglas Fisher Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,174
+48.15%
|
-
|
|
Oct 24
2023
|
Ronald Asbury Andrews Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,005
+48.18%
|
-
|
|
Oct 24
2023
|
David Seth Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,905
+9.07%
|
-
|
|
Oct 24
2023
|
Richard A Sandberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,510
+42.6%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 50.3K shares |
|---|
| Open market or private sale | 2K shares |
|---|